Literature DB >> 3075357

Comparative studies of drug susceptibility of five strains of Trypanosoma cruzi in vivo and in vitro.

R A Neal1, J van Bueren.   

Abstract

A comparative study showed that 5 laboratory strains of Trypanosoma cruzi could be divided into a non-responsive group (Sonya clone and Colombiana) and a responsive group (Tulahuén, Y and Peru), based on long-term treatment of mouse infections with nifurtimox and benznidazole. In vitro sensitivity of epimastigotes and blood-stream trypomastigotes in macrophage cultures did not distinguish the strains, nor did the rate of development of nifurtimox resistance by epimastigote cultures. 7 novel anti-T. cruzi compounds also behaved similarly with respect to the 2 groups. A small decrease in sensitivity was observed in vitro by non-responsive strains of T. cruzi after re-isolation from treated mice. It is postulated that there could be an immunological component involved in successful treatment of T. cruzi infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3075357     DOI: 10.1016/0035-9203(88)90208-8

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  20 in total

1.  Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.

Authors:  Victor B Saraiva; Daniel Gibaldi; José O Previato; Lucia Mendonça-Previato; Marcelo T Bozza; Célio G Freire-De-Lima; Norton Heise
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease.

Authors:  Kathryn Jones; Leroy Versteeg; Ashish Damania; Brian Keegan; April Kendricks; Jeroen Pollet; Julio Vladimir Cruz-Chan; Fabian Gusovsky; Peter J Hotez; Maria Elena Bottazzi
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

3.  Population pharmacokinetics of benznidazole in adult patients with Chagas disease.

Authors:  D Soy; E Aldasoro; L Guerrero; E Posada; N Serret; T Mejía; J A Urbina; J Gascón
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

4.  Potent anti-Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors.

Authors:  F S Buckner; J H Griffin; A J Wilson; W C Van Voorhis
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 5.  Between a bug and a hard place: Trypanosoma cruzi genetic diversity and the clinical outcomes of Chagas disease.

Authors:  Louisa A Messenger; Michael A Miles; Caryn Bern
Journal:  Expert Rev Anti Infect Ther       Date:  2015-08       Impact factor: 5.091

6.  Differential gene expression in benznidazole-resistant Trypanosoma cruzi parasites.

Authors:  Diana Villarreal; Philippe Nirdé; Mallorie Hide; Christian Barnabé; Michel Tibayrenc
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

7.  Further insights into biological evaluation of new anti-Trypanosoma cruzi 5-nitroindazoles.

Authors:  Cristina Fonseca-Berzal; José Antonio Escario; Vicente J Arán; Alicia Gómez-Barrio
Journal:  Parasitol Res       Date:  2014-01-17       Impact factor: 2.289

8.  Experimental chemotherapy of Trypanosoma cruzi infection: persistence of parasite antigens and positive serology in parasitologically cured mice.

Authors:  S G Andrade; L A Freitas; S Peyrol; A R Pimentel; M Sadigursky
Journal:  Bull World Health Organ       Date:  1991       Impact factor: 9.408

9.  Molecular characterization of cytosolic and mitochondrial tryparedoxin peroxidase in Trypanosoma cruzi populations susceptible and resistant to benznidazole.

Authors:  Fernanda B Nogueira; Jerônimo C Ruiz; Carlos Robello; Alvaro J Romanha; Silvane M F Murta
Journal:  Parasitol Res       Date:  2008-11-19       Impact factor: 2.289

10.  New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice.

Authors:  Juan M Bustamante; Julie M Craft; Byron D Crowe; Sarah A Ketchie; Rick L Tarleton
Journal:  J Infect Dis       Date:  2013-08-14       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.